190 related articles for article (PubMed ID: 28433497)
1. Clostridium difficile toxin glucosyltransferase domains in complex with a non-hydrolyzable UDP-glucose analogue.
Alvin JW; Lacy DB
J Struct Biol; 2017 Jun; 198(3):203-209. PubMed ID: 28433497
[TBL] [Abstract][Full Text] [Related]
2. Structural determinants of Clostridium difficile toxin A glucosyltransferase activity.
Pruitt RN; Chumbler NM; Rutherford SA; Farrow MA; Friedman DB; Spiller B; Lacy DB
J Biol Chem; 2012 Mar; 287(11):8013-20. PubMed ID: 22267739
[TBL] [Abstract][Full Text] [Related]
3. The structure of Clostridium difficile toxin A glucosyltransferase domain bound to Mn2+ and UDP provides insights into glucosyltransferase activity and product release.
D'Urzo N; Malito E; Biancucci M; Bottomley MJ; Maione D; Scarselli M; Martinelli M
FEBS J; 2012 Sep; 279(17):3085-97. PubMed ID: 22747490
[TBL] [Abstract][Full Text] [Related]
4. Use of a neutralizing antibody helps identify structural features critical for binding of
Kroh HK; Chandrasekaran R; Rosenthal K; Woods R; Jin X; Ohi MD; Nyborg AC; Rainey GJ; Warrener P; Spiller BW; Lacy DB
J Biol Chem; 2017 Sep; 292(35):14401-14412. PubMed ID: 28705932
[No Abstract] [Full Text] [Related]
5. Development of a non-radiolabeled glucosyltransferase activity assay for C. difficile toxin A and B using ultra performance liquid chromatography.
Loughney JW; Lancaster C; Price CE; Hoang VM; Ha S; Rustandi RR
J Chromatogr A; 2017 May; 1498():169-175. PubMed ID: 28238427
[TBL] [Abstract][Full Text] [Related]
6. Toward a structural understanding of Clostridium difficile toxins A and B.
Pruitt RN; Lacy DB
Front Cell Infect Microbiol; 2012; 2():28. PubMed ID: 22919620
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Clostridium difficile TcdA and TcdB toxins with transition state analogues.
Paparella AS; Aboulache BL; Harijan RK; Potts KS; Tyler PC; Schramm VL
Nat Commun; 2021 Nov; 12(1):6285. PubMed ID: 34725358
[TBL] [Abstract][Full Text] [Related]
8. Autocatalytic processing of Clostridium difficile toxin B. Binding of inositol hexakisphosphate.
Egerer M; Giesemann T; Herrmann C; Aktories K
J Biol Chem; 2009 Feb; 284(6):3389-95. PubMed ID: 19047051
[TBL] [Abstract][Full Text] [Related]
9. A neutralizing antibody that blocks delivery of the enzymatic cargo of
Kroh HK; Chandrasekaran R; Zhang Z; Rosenthal K; Woods R; Jin X; Nyborg AC; Rainey GJ; Warrener P; Melnyk RA; Spiller BW; Lacy DB
J Biol Chem; 2018 Jan; 293(3):941-952. PubMed ID: 29180448
[No Abstract] [Full Text] [Related]
10. Structural organization of the functional domains of Clostridium difficile toxins A and B.
Pruitt RN; Chambers MG; Ng KK; Ohi MD; Lacy DB
Proc Natl Acad Sci U S A; 2010 Jul; 107(30):13467-72. PubMed ID: 20624955
[TBL] [Abstract][Full Text] [Related]
11. High temporal resolution of glucosyltransferase dependent and independent effects of Clostridium difficile toxins across multiple cell types.
D'Auria KM; Bloom MJ; Reyes Y; Gray MC; van Opstal EJ; Papin JA; Hewlett EL
BMC Microbiol; 2015 Feb; 15(1):7. PubMed ID: 25648517
[TBL] [Abstract][Full Text] [Related]
12. Functional defects in
Gupta P; Zhang Z; Sugiman-Marangos SN; Tam J; Raman S; Julien JP; Kroh HK; Lacy DB; Murgolo N; Bekkari K; Therien AG; Hernandez LD; Melnyk RA
J Biol Chem; 2017 Oct; 292(42):17290-17301. PubMed ID: 28842504
[No Abstract] [Full Text] [Related]
13. UDP-glucose deficiency in a mutant cell line protects against glucosyltransferase toxins from Clostridium difficile and Clostridium sordellii.
Chaves-Olarte E; Florin I; Boquet P; Popoff M; von Eichel-Streiber C; Thelestam M
J Biol Chem; 1996 Mar; 271(12):6925-32. PubMed ID: 8636120
[TBL] [Abstract][Full Text] [Related]
14.
Paparella AS; Cahill SM; Aboulache BL; Schramm VL
ACS Chem Biol; 2022 Sep; 17(9):2507-2518. PubMed ID: 36038138
[TBL] [Abstract][Full Text] [Related]
15. Auto-catalytic cleavage of Clostridium difficile toxins A and B depends on cysteine protease activity.
Egerer M; Giesemann T; Jank T; Satchell KJ; Aktories K
J Biol Chem; 2007 Aug; 282(35):25314-21. PubMed ID: 17591770
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of Clostridium difficile toxin A.
Chumbler NM; Rutherford SA; Zhang Z; Farrow MA; Lisher JP; Farquhar E; Giedroc DP; Spiller BW; Melnyk RA; Lacy DB
Nat Microbiol; 2016 Jan; 1():15002. PubMed ID: 27571750
[TBL] [Abstract][Full Text] [Related]
17. Isofagomine Inhibits Multiple TcdB Variants and Protects Mice from
Paparella AS; Brew I; Hong HA; Ferriera W; Cutting S; Lamiable-Oulaidi F; Popadynec M; Tyler PC; Schramm VL
ACS Infect Dis; 2024 Mar; 10(3):928-937. PubMed ID: 38334357
[No Abstract] [Full Text] [Related]
18. Structure of the glucosyltransferase domain of TcdA in complex with RhoA provides insights into substrate recognition.
Chen B; Liu Z; Perry K; Jin R
Sci Rep; 2022 May; 12(1):9028. PubMed ID: 35637242
[TBL] [Abstract][Full Text] [Related]
19. Clostridium difficile Toxins TcdA and TcdB Cause Colonic Tissue Damage by Distinct Mechanisms.
Chumbler NM; Farrow MA; Lapierre LA; Franklin JL; Lacy DB
Infect Immun; 2016 Oct; 84(10):2871-7. PubMed ID: 27456833
[TBL] [Abstract][Full Text] [Related]
20. Phylogenomics of 8,839 Clostridioides difficile genomes reveals recombination-driven evolution and diversification of toxin A and B.
Mansfield MJ; Tremblay BJ; Zeng J; Wei X; Hodgins H; Worley J; Bry L; Dong M; Doxey AC
PLoS Pathog; 2020 Dec; 16(12):e1009181. PubMed ID: 33370413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
